Write in a clean editor, then format for Boletín Médico del Hospital Infantil de México in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Boletín Médico del Hospital Infantil de México is a peer-reviewed journal published by Elsevier, covering Health and Lifestyle Studies, Child and Adolescent Health, Ethics and bioethics in healthcare.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Boletín Médico del Hospital Infantil de México 12 (2023) 45–58.
Formats any DOI in Boletín Médico del Hospital Infantil de México style. No sign-up. |
| Publishes research in | Health and Lifestyle Studies Child and Adolescent Health Ethics and bioethics in healthcare Neonatal Respiratory Health Research Infant Development and Preterm Care |
| ISSN | 0539-6115 |
| Citation impact (2-yr) | 0.32 |
| h-index | 23 |
| i10-index | 129 |
| Total citations | 5,527 |
| Open access | Yes |
| Top institutions publishing here | Hospital Infantil de México Federico Gómez |
| Journal website | bmhim.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
With standardized screening tools, research studies have shown that developmental disabilities can be detected reliably and with validity in children as young as 4 months of age by using the instruments such as the Ages and Stages Questionnaire. In this review, we will focus on one tool, the Ages and Stages Questionnaire, to illustrate the…
Before the severe acute respiratory syndrome outbreak in 2003, coronaviruses (CoVs) were not considered to be highly pathogenic to humans. However, it was this epidemic that highlighted this group of viruses and included them among the causative agents of emerging epidemic diseases. In addition, in 2012, another new CoV responsible for the Middle East respiratory…
Developing a novel drug is a complex, risky, expensive and time-consuming venture. It is estimated that the conventional drug discovery process ending with a new medicine ready for the market can take up to 15 years and more than a billion USD. Fortunately, this scenario has recently changed with the arrival of new approaches. Many…
Over the past decade, some studies have addressed the therapeutic effects of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) and the opposite effects of omega-6 (ω-6) PUFAs on several diseases, including cardiovascular disorders, diabetes, neurodegenerative diseases, and cancer. Research demonstrates the safety of these naturally occurring ingredients. Of particular interest, several studies have shown that ω-3…
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Alphainfluenzavirus are RNA viruses that cause coronavirus disease-19 and influenza, respectively. Both viruses infect the respiratory tract, show similar symptoms, and use surface proteins to infect the host. Influenza requires hemagglutinin and neuraminidase to infect, whereas SARS-CoV-2 uses protein S. Both viruses depend on a viral RNA…
